ADC Therapy for Metastatic HR+/HER2- BC

By University of Illinois Cancer Center FEATURING V.K. Gadi

156 views

December 6, 2024

Disclaimer: On January 17, 2025 the FDA has approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adult patients with unresectable or metastatic, HR+/HER2- breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

Comments 0